ERBB2 and breast cancer: This study aimed to evaluate the clinical, economic and societal impact of adding pertuzumab to trastuzumab and chemotherapy in HER2-positive early BC patients, in order to provide additional information to help decision makers on the role of pertuzumab and its reimbursement in Italy.